Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole as adjunctive therapy in OCD
NCT03299166Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of troriluzole in obsessive compulsive disorder (OCD), sponsored by Biohaven Ltd.. Started Dec 2017; status: completed.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT03299166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299166.